Literature DB >> 26315872

124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.

Angelina Cistaro1, Natale Quartuccio, Federico Caobelli, Arnoldo Piccardo, Rosario Paratore, Pietro Coppolino, Alessandro Sperandeo, Gaspare Arnone, Umberto Ficola.   

Abstract

Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26315872     DOI： 10.5603/NMR.2015.0024

Source DB:  PubMed          Journal:  Nucl Med Rev Cent East Eur        ISSN： 1506-9680


  15 in total

Review 1.  Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.

Authors:  Youngho Seo
Journal:  Nucl Med Mol Imaging       Date:  2019-02-18

2.  Guidelines on nuclear medicine imaging in neuroblastoma.

Authors:  Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10       Impact factor: 9.236

Review 3.  Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

Authors:  David Taïeb; Abhishek Jha; Giorgio Treglia; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

Review 4.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Julie R Park; Rochelle Bagatell; Susan L Cohn; Andrew D Pearson; Judith G Villablanca; Frank Berthold; Susan Burchill; Ariane Boubaker; Kieran McHugh; Jed G Nuchtern; Wendy B London; Nita L Seibel; O Wolf Lindwasser; John M Maris; Penelope Brock; Gudrun Schleiermacher; Ruth Ladenstein; Katherine K Matthay; Dominique Valteau-Couanet
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

Review 5.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

Review 6.  A review of neuroblastoma image-defined risk factors on magnetic resonance imaging.

Authors:  Alan M Chen; Andrew T Trout; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2018-08-04

Review 7.  Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

Authors:  Jia Xia; Hang Zhang; Qun Hu; Shuang-You Liu; Liu-Qing Zhang; Ai Zhang; Xiao-Ling Zhang; Ya-Qin Wang; Ai-Guo Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

Review 8.  The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.

Authors:  Nancy Ratner; Garrett M Brodeur; Russell C Dale; Nina F Schor
Journal:  Ann Neurol       Date:  2016-04-30       Impact factor: 10.422

9.  First-in-Man Evaluation of 124I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment.

Authors:  Richard Laforest; Farrokh Dehdashti; Yongjian Liu; Jennifer Frye; Sarah Frye; Hannah Luehmann; Deborah Sultan; Joseph S Shan; Bruce D Freimark; Barry A Siegel
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

10.  Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma.

Authors:  Yen-Lin Liu; Meng-Yao Lu; Hsiu-Hao Chang; Ching-Chu Lu; Dong-Tsamn Lin; Shiann-Tarng Jou; Yung-Li Yang; Ya-Ling Lee; Shiu-Feng Huang; Yung-Ming Jeng; Hsinyu Lee; James S Miser; Kai-Hsin Lin; Yung-Feng Liao; Wen-Ming Hsu; Kai-Yuan Tzen
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.